Methylene blue and its importance in medicine
Level 5 - mechanism / opinion, no new human data
Narrative review discussing mechanisms and therapeutic uses without systematic methodology or primary human data
OpenAlex W3119795901 · doi:10.5606/fng.btd.2020.25035
What was done
This narrative review summarizes the history, chemical properties, and therapeutic mechanisms of methylene blue, focusing on its applications as an antimalarial, an antioxidant in Alzheimer's disease, and an antifungal agent against Candida infections.
What was found
The abstract reports no quantitative data, effect sizes, or sample statistics. It describes mechanisms qualitatively: methylene blue regulates redox cycling via leucomethylene blue, inhibits Plasmodium falciparum glutathione reductase and induces parasite-selective oxidative stress, reduces tau protein accumulation and mitochondrial reactive oxygen species in Alzheimer's models, and promotes mitochondrial dysfunction in yeast.
Why it matters
The review summarizes how methylene blue's core redox and mitochondrial properties are applied across infectious and neurodegenerative disease mechanisms.
Limits
As an unsystematic narrative review, it presents no primary clinical trial data, quantitative outcomes, or systematic literature search methodology. Efficacy and safety outcomes in human populations are not reported in the abstract.
Cited by
- context Methylene blue was the first drug ever discovered.